If you have been reading about GABA-A receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
2 AgNO3 → 2 Ag + O2 + 2 NO2 Most metal nitrates thermally decompose to the respective oxides. This may be the case for silver nitrate. Unlike most metal oxides, however, silver oxide readily degrades to the elemental silver.
== Working == A basic TDLAS setup consists of a tunable diode laser light source, transmitting (i.e. beam shaping) optics, optically accessible absorbing medium, receiving optics and detector/s. The emission wavelength of the tunable diode laser, viz. VCSEL, DFB, etc., is tuned over the characteristic absorption lines of a species in the gas in the path of the laser beam. This causes a reduction of the measured signal intensity due to absorption, which can be detected by a photodiode, and then used to determine the gas concentration and other properties as described later. Different diode lasers are used based on the application and the range over which tuning is to be performed. Typical examples are InGaAsP/InP (tunable over 900 nm to 1.6 μm), InGaAsP/InAsP (tunable over 1.6 μm to 2.2 μm), etc. These lasers can be tuned by either adjusting their temperature or by changing injection current density into the gain medium. While temperature changes allow tuning over 100 cm−1, it is limited by slow tuning rates (a few hertz), due to the thermal inertia of the system. On the other hand, adjusting the injection current can provide tuning at rates as high as ~10 GHz, but it is restricted to a smaller range (about 1 to 2 cm−1) over which the tuning can be performed. The typical laser linewidth is of the order of 10−3 cm−1 or smaller. Additional tuning, and linewidth narrowing, methods include the use of extracavity dispersive optics.
A group of individuals who share a common trait, such as birth year. In medicine, a cohort is a group that is part of a clinical trial or study and is observed over a period of time. (NCI) In epidemiology, a group of individuals with some characteristics in common. (NLM) Cohort study
=== Prosecution === In his opening statement, prosecutor Brian Leveson portrayed the Wests as sadistic sex-obsessed murderers, terming the bodies discovered at Cromwell Street and Midland Road "secrets more terrible than words can express ... [The victims'] last moments on earth were as objects of the sexual depravity of this woman and her husband." He pointed out that Fred had been incarcerated when Charmaine was killed, claimed that Fred and Rose had each learned from their mistake in allowing Owens to live, and said that the gag on victim Thérèse Siegenthaler evinced a "feminine" touch—a scarf tied in a bow. Leveson promised to demonstrate Rose's controlling and sexually sadistic character, as well as her efforts to deflect suspicion about the disappearance of their victims. Prosecution witnesses included Cromwell Street lodgers, victims' relatives, Rose's mother, Daisy, and sister, Glenys, and surviving victims including Kathryn Halliday (a former lover of Fred and Rose), Owens, Anne Marie and a "Miss A" (who had been sexually assaulted at age 14 by Fred and Rose in 1977 and who described Rose as the more aggressive perpetrator of the two). Neighbours described Charmaine's 1971 disappearance while Fred was imprisoned and Rose's casual indifference to Heather's disappearance. Rose's counsel, Dick Ferguson, tried to discredit prosecution witnesses as either having financially exploited their connection to the case or being motivated by grudges.
=== NNPC, NEITI Set Up Joint Committee to Strengthen Transparency === In keeping with the Transparency, Accountability, and Performance Excellence (TAPE) agenda of the Mele Kyari-led management of the Nigerian National Petroleum Corporation (NNPC), the corporation and the Nigeria Extractive Industries Transparency Initiative (NEITI) have set up a joint committee to deepen collaboration in order to promote transparency in the Oil and Gas Industry. Speaking at the inauguration of the NNPC-NEITI Joint Committee on Mainstreaming and Remedial Issues, group managing director of NNPC, Kyari, said the joint committee was part of efforts to further deepen the robust history of collaboration that both organisations had enjoyed over the years. He said NNPC was in complete sync with the activities of NEITI because it was the right of the over 200 million Nigerians who are the shareholders of the corporation to know everything about the operations of their company.
Sources: en.wikipedia.org
A ceasefire was reached between Israel and Hezbollah at the end of the 2006 Lebanon War, based on the terms of UN Security Council Resolution 1701 which called for a demilitarized zone between the southern border of Lebanon and the Litani river. The UN Security Council resolution mandated only the Lebanese army and United Nations Interim Force in Lebanon (UNIFIL) could be armed in southern Lebanon. It also stated that neither side should cross the Blue Line, which marks the border between Lebanon and the Golan Heights, and divides the village of Ghajar between the two. Despite this, both Israel and Hezbollah have outstanding obligations under UNSCR 1701. Since 2006, Hezbollah fortified southern Lebanon, obstructed UNIFIL's access, built tunnels into Israel, and crossed the Blue Line. Israel has also accused Hezbollah of using a local environmental organization as a front for its military activities near the Blue Line. After retreating behind the Blue Line in 2000, Israel reoccupied the whole of Ghajar in 2006, including the Lebanese part of the village. Israel continues to occupy Ghajar and an adjacent area, and has repeatedly breached Lebanese airspace, waters, and borders. UNIFIL reports that Israel entered Lebanese airspace on more than 22,000 occasions between 2007 and 2021.
=== Nuclear weapons decommissioning === Waste from nuclear weapons decommissioning is unlikely to contain much beta or gamma activity other than tritium and americium. It is more likely to contain alpha-emitting actinides such as Pu-239 which is a fissile material used in nuclear bombs, plus some material with much higher specific activities, such as Pu-238 or Po. In the past the neutron trigger for an atomic bomb tended to be beryllium and a high activity alpha emitter such as polonium; an alternative to polonium is Pu-238. For reasons of national security, details of the design of modern nuclear bombs are normally not released to the open literature. Some designs might contain a radioisotope thermoelectric generator using Pu-238 to provide a long-lasting source of electrical power for the electronics in the device. It is likely that the fissile material of an old nuclear bomb, which is due for refitting, will contain decay products of the plutonium isotopes used in it. These are likely to include U-236 from Pu-240 impurities plus some U-235 from decay of the Pu-239; due to the relatively long half-life of these Pu isotopes, these wastes from radioactive decay of bomb core material would be very small, and in any case, far less dangerous (even in terms of simple radioactivity) than the Pu-239 itself.
== GLP-1, GIP, and glucagon receptor triple agonists == Following the discovery of GLP-1/GIP and GLP-1/glucagon dual agonists, it was hoped that a triple agonist would provide additive or synergistic metabolic benefits. A clinical trial of the triple agonist retatrutide found an average 24.2% weight reduction in the highest dosage group after 24 weeks. Another clinical trial of triple agonist UBT-251 also found an average weight reduction of 19.7% after 24 weeks.
Pyruvate is taken up by a specific, low Km transporter to bring it into the mitochondrial matrix for oxidation by the pyruvate dehydrogenase complex. The phosphate carrier (PiC) mediates the electroneutral exchange (antiport) of phosphate (H2PO−4; Pi) for OH− or symport of phosphate and protons (H+) across the inner membrane, and the driving force for moving phosphate ions into the mitochondria is the proton motive force. The ATP-ADP translocase (also called adenine nucleotide translocase, ANT) is an antiporter and exchanges ADP and ATP across the inner membrane. The driving force is due to the ATP (−4) having a more negative charge than the ADP (−3), and thus it dissipates some of the electrical component of the proton electrochemical gradient. The outcome of these transport processes using the proton electrochemical gradient is that more than 3 H+ are needed to make 1 ATP. Obviously, this reduces the theoretical efficiency of the whole process and the likely maximum is closer to 28–30 ATP molecules. In practice the efficiency may be even lower because the inner membrane of the mitochondria is slightly leaky to protons. Other factors may also dissipate the proton gradient creating an apparently leaky mitochondria. An uncoupling protein known as thermogenin is expressed in some cell types and is a channel that can transport protons. When this protein is active in the inner membrane it short circuits the coupling between the electron transport chain and ATP synthesis. The potential energy from the proton gradient is not used to make ATP but generates heat.
== Most recent publications == Perez-Riverol, Yasset; Bai, Mingze; da Veiga Leprevost, Felipe; Squizzato, Silvano; Park, Young Mi; Haug, Kenneth; Carroll, Adam J; Spalding, Dylan; Paschall, Justin; Wang, Mingxun; del-Toro, Noemi; Ternent, Tobias; Zhang, Peng; Buso, Nicola; Bandeira, Nuno; Deutsch, Eric W; Campbell, David S; Beavis, Ronald C; Salek, Reza M; Sarkans, Ugis; Petryszak, Robert; Keays, Maria; Fahy, Eoin; Sud, Manish; Subramaniam, Shankar; Barbera, Ariana; Jiménez, Rafael C; Nesvizhskii, Alexey I; Sansone, Susanna-Assunta; Steinbeck, Christoph; Lopez, Rodrigo; Vizcaíno, Juan A; Ping, Peipei; Hermjakob, Henning (2017). "Discovering and linking public omics data sets using the Omics Discovery Index". Nature Biotechnology. 35 (5): 406–409. doi:10.1038/nbt.3790. ISSN 1087-0156. PMC 5831141. PMID 28486464. Omenn, Gilbert S.; Lane, Lydie; Lundberg, Emma K.; Beavis, Ronald C.; Overall, Christopher M.; Deutsch, Eric W. (2016). "Metrics for the Human Proteome Project 2016: Progress on Identifying and Characterizing the Human Proteome, Including Post-Translational Modifications". Journal of Proteome Research. 15 (11): 3951–3960. doi:10.1021/acs.jproteome.6b00511. ISSN 1535-3893. PMC 5129622. PMID 27487407. Spicer, Vic; Ezzati, Peyman; Neustaeter, Haley; Beavis, Ronald C.; Wilkins, John A.; Krokhin, Oleg V. (2016). "3D HPLC-MS with Reversed-Phase Separation Functionality in All Three Dimensions for Large-Scale Bottom-Up Proteomics and Peptide Retention Data Collection". Analytical Chemistry. 88 (5): 2847–2855. doi:10.1021/acs.analchem.5b04567. ISSN 0003-2700. PMID 26849966.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.